The In Vitro Diagnostic market values established companies with regulatory approval and market traction. This is demonstrated by premiums paid for acquisitions of companies that offer the opportunity to quickly capture market share and IPOs of companies with significant revenues.
Market Insight: Craig Steger, Oded Ben-Joseph, PhD, MBA, Echoe M. Bouta, PhD
The In Vitro Diagnostic market values established companies with regulatory approval and market traction. This is demonstrated by premiums paid for acquisitions of companies that offer the opportunity to quickly capture market share and IPOs of companies with significant revenues.
Driven by a multitude of factors including the ageing population, increasing burden of chronic and infectious diseases, mounting demand for early diagnosis, emergence of personalized medicine and higher demand for testing in the developing world, the global In Vitro Diagnostics (IVD) market is projected to grow at 5.2% CAGR from $68 billion in 2018 to $88 billion in 2023. We examined recent IVD market dynamics between 2016 and Q3/2019 including financing events, merger and acquisitions (M&As) and initial public offerings (IPOs). We analyzed these dynamics to assess the overall activity of the segment to provide management teams and boards with a market-aligned perspective.
BOSTON– February 26, 2025 – Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, congratulates RealizedCare on the success of their company, and acquisition by XRHealth. Outcome Capital served as the exclusive strategic and financial advisor to RealizedCare. Through their digitally-powered care management triage platform and therapeutic solutions, RealizedCare […]
Read MoreOutcome Capital Life Science Market Pulse January 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?